Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy

1999 ◽  
Vol 6 (4) ◽  
pp. 178-183 ◽  
Author(s):  
Tsunenori Kondo ◽  
Shiro Onitsuka ◽  
Osamu Ryoji ◽  
Takeshi Kihara ◽  
Yukiko Goto ◽  
...  
1992 ◽  
Vol 21 (2) ◽  
pp. 89-97 ◽  
Author(s):  
J.A. Witjes ◽  
L.A.L.M. Kiemeney ◽  
G.O.N. Oosterhof ◽  
F.M.J. Debruyne

1988 ◽  
Vol 139 (5) ◽  
pp. 941-944 ◽  
Author(s):  
Ralph J. Torrence ◽  
Louis R. Kavoussi ◽  
William J. Catalona ◽  
Timothy L. Ratliff

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14560-14560
Author(s):  
F. Merlin ◽  
M. Riolfi ◽  
T. Sava ◽  
F. Consoli ◽  
C. Griso ◽  
...  

14560 Background: Transitional cell carcinomas (TCC) of the renal pelvis and ureter are relatively uncommon. An important characteristic of TCC is multifocality throughout the all urinary tract simultaneously and/or subsequently. To clarify the association between UTTCC and bladder tumors, we retrospectively analysed 86 patients with UTTCC in order to evaluate prognostic factors for recurrence and to identify risk factors for development of bladder cancers. Methods: All 86 upper tract transitional cell carcinoma patients (pts) were treated surgically between January 1988 and July 2005. Median age was 69 years (range: 34–91). We observed a male predominance (71%) and 78% of patients were heavy smokers. Forty-five (52.3%) patients had a diagnosis of bladder transitional carcinoma. The median age of this group of patients was 70 range 40–87). In fifteen cases (17%), bladder tumour occurred first than upper tract neoplasia; in 14 patients bladder and upper tract tumours were synchronous. Results: Median survival was 97 months; 49 (57%) patients are alive and 43 are disease-free. Grading, stage T, lympho-vascular invasion and squamous differentiation were significant prognostic factors for systemic relapse (p < 0.05). Twenty-eight pts (32.5%) developed subsequent transitional bladder cancer after a median time of 12 months; multifocality of primitive tumours was significant predictive factor. Invasive UTTCC were less likely associated with bladder cancer. We observed that superficial bladder cancer developed more frequently in pts with well differentiated (G1–2) primitive cancer (90% of cases), without lympho-vascular invasion and with history of heavy smoke exposition. Conclusions: In our study, T, N and G confirmed to be the most important prognostic factors for systemic relapse. Lympho-vascular invasion highly predicts metastasis. Our analysis highlights that upper urinary tract cancers seem to have different history and different pattern of association with bladder tumours, according to specific prognostic factors. The development of recurrent superficial bladder cancer is more frequently associated with small well differentiated multifocal upper tract tumours.Therefore follow-up should be oriented according to these characteristics. No significant financial relationships to disclose.


1986 ◽  
Vol 18 (4) ◽  
pp. 417-420 ◽  
Author(s):  
H. A. Özen ◽  
A. Akdaş ◽  
T. Alkibay ◽  
U. Altuĝ ◽  
D. Remzi

2008 ◽  
Vol 179 (4S) ◽  
pp. 71-71
Author(s):  
Luiz C Neves de Oliveira ◽  
Marcos F Dall'Oglio ◽  
Cesar Camara ◽  
Jose Pontes ◽  
Adriano Nesrallah ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Tomonori Kato ◽  
Kazushi Nomura ◽  
Fukuo Kondo ◽  
Masami Wakisaka ◽  
Akira Komiya

The high incidence of tumor recurrence following transurethral resection (TUR) represents a major problem encountered in the management of bladder cancer. This study examined the efficacy of intravesical chemotherapy in superficial bladder cancer. We retrospectively analyzed 90 Japanese cases with low-grade superficial transitional cell carcinoma (stage T1, grades 1 and 2) who were rendered tumor-free by TURBT (TUR of bladder tumor) and who thereafter were treated with or without intravesical chemotherapy. Among them, instillation was terminated in 2 patients due to adverse effects (severe but reversible chemical cystitis). Remaining 88 patients were divided into 2 groups according to therapy: the TURBT-only group(n=46), defined as patients treated with TURBT alone, and the Instillation group(n=42), defined as patients treated with weekly intravesical instillation therapies using epirubicin plus Ara-C. Recurrence-free rate was significantly higher in the Instillation group than in the TURBT-only group (p=0.02, HR = 0.457). The 5-year recurrence-free rate was 58.5% for the Instillation group and 38.6% for the TURBT-only group. Our instillation schedule represents the most intensive regimen among previously reported therapies and resulted in a 54.3% decrease in incidence of tumor recurrence. We believe that the results of this study could provide useful information on management of bladder cancer.


2000 ◽  
pp. 73 ◽  
Author(s):  
F. MILL??N-RODR|fGUEZ ◽  
G. CH??CHILE-TONIOLO ◽  
J. SALVADOR-BAYARRI ◽  
J. PALOU ◽  
J. VICENTE-RODR|fGUEZ

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Canan Küçükgergin ◽  
Akin S. Amasyali ◽  
Oner Sanli ◽  
Selcuk Erdem ◽  
Faruk Ozcan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document